Exl01

5 trials 5 recruiting

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

5 Recruiting

0 Completed trials

5 Sponsors

1 Countries

Phase II

Phase I/II

Phase II: 3 Phase I/II: 2

Sponsors using this IMP

Centre De Lutte Contre Le Cancer Eugene Marquis 1 Centre Hospitalier Universitaire De Nantes 1 Gercor 1 Groupe De Recherche Sur Les Maladies Inflammatoires Digestives 1 Hospices Civils De Lyon 1

All trials

5 total

MAINTAIN-POP: EXL01 and prevention of post-operative recurrence of Crohn's disease Recruiting

2024-511357-22-00 Phase II 1 country Groupe De Recherche Sur Les Maladies Inflammatoires Digestives
MICROBIOTA MODIFICATION FOR IMMUNO-ONCOLOGY IN HEPATOCELLULAR CARCINOMA - “MOTHER” Recruiting

2023-508201-25-00 Phase II 1 country Centre De Lutte Contre Le Cancer Eugene Marquis
EXLIBRIS : “EXL-01 combined with nivolumab for advanced NSCLC refractory to immunotherapy” Recruiting

2023-505285-28-01 Phase I/II 1 country Centre Hospitalier Universitaire De Lille
Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metas… Recruiting

2023-506753-38-00 Phase II 1 country Gercor
Evaluation of EXL01 a new Live Biotherapeutic Product to prevent recurrence of Clostridioides difficile infection in high-risk patients. LIV… Recruiting

2023-506232-32-00 Phase I/II 1 country Hospices Civils De Lyon

Showing 1–5 of 5 trials

← All drugs A–Z